FGF2 and ulcer disease: In 2000, recombinant human basic fibroblast growth factor (rb-FGF2) was approved for use by the Chinese Food and Drug Administration for the treatment of chronic wounds including chronic granulating wounds, ulcers and bedsores, fresh wounds (trauma and surgical wounds) and burn wounds (superficial degree burn, deep second degree burns, and granulation wounds).